Artiva Biotherapeutics reports RSU grant and option exchange

Artiva Biotherapeutics granted its Chief Tech Operations Officer 107,156 restricted stock units (RSUs) of common stock on December 12, 2025 under its 2024 Equity Incentive Plan as part of an option exchange.

Accepted by SEC EDGAR 12/12/2025 - 07:20 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

Artiva Biotherapeutics granted its Chief Tech Operations Officer 107,156 restricted stock units (RSUs) of common stock on December 12, 2025 under its 2024 Equity Incentive Plan as part of an option exchange.

On the same date, the company cancelled employee stock options covering 77,519 and 9,119 shares at an exercise price of $5.01 and options for 20,519 shares at $13.47, in exchange for the new RSUs. After these transactions, the officer directly beneficially owns 185,339 shares of Artiva common stock.

Insider Trade Summary

4 transactions reported

Mixed 4 txns

Insider Horan Christopher

Role Chief Tech Operations Officer

Type	Security	Shares	Price	Value
Disposition	Employee Stock Option (Right to Buy)	77,519	$0.00	$0.00
Disposition	Employee Stock Option (Right to Buy)	9,119	$0.00	$0.00
Disposition	Employee Stock Option (Right to Buy)	20,519	$0.00	$0.00
Grant/Award	Common Stock	107,156	$0.00	$0.00

Holdings After Transaction: Employee Stock Option (Right to Buy) — 0 contracts (Direct); Common Stock — 185,339 shares (Direct)

Holdings Before and After: Employee Stock Option (Right to Buy), 107,157 to 0 contracts (Direct); Common Stock, 78,183 to 185,339 shares (Direct)

Footnotes (5)

1. F1. Represents restricted stock units award granted under the Issuer's 2024 Equity Incentive Plan ("RSUs").
2. F2. On December 12, 2025, the Issuer cancelled, pursuant to an option exchange, the options listed in Table II. In exchange for the cancelled options, the Reporting Person received the RSUs reported in Table I.
3. F3. 25% of the shares vested on December 31, 2022, and the remaining shares vest in 36 equal monthly installments thereafter.
4. F4. Vesting is monthly over a 48-month period starting May 24, 2023 in equal monthly amounts.
5. F5. 25% of the shares will vest on July 19, 2025, and the remaining shares vest in 36 equal monthly installments thereafter.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Horan Christopher

(Last) (First) (Middle)

C/O ARTIVA BIOTHERAPEUTICS, INC.

5505 MOREHOUSE DRIVE, SUITE 100

(Street)

SAN DIEGO CA 92121

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Artiva Biotherapeutics, Inc. [ ARTV ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Tech Operations Officer

3. Date of Earliest Transaction (Month/Day/Year)
12/12/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	12/12/2025		A		107,156(1)	A	$0(2)	185,339	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (Right to Buy)	$5.01	12/12/2025		D			77,519	(3)	04/02/2033	Common Stock	77,519	(2)	0	D
Employee Stock Option (Right to Buy)	$5.01	12/12/2025		D			9,119	(4)	05/23/2033	Common Stock	9,119	(2)	0	D
Employee Stock Option (Right to Buy)	$13.47	12/12/2025		D			20,519	(5)	05/01/2034	Common Stock	20,519	(2)	0	D

Explanation of Responses:

1. Represents restricted stock units award granted under the Issuer's 2024 Equity Incentive Plan ("RSUs").

2. On December 12, 2025, the Issuer cancelled, pursuant to an option exchange, the options listed in Table II. In exchange for the cancelled options, the Reporting Person received the RSUs reported in Table I.

3. 25% of the shares vested on December 31, 2022, and the remaining shares vest in 36 equal monthly installments thereafter.

4. Vesting is monthly over a 48-month period starting May 24, 2023 in equal monthly amounts.

5. 25% of the shares will vest on July 19, 2025, and the remaining shares vest in 36 equal monthly installments thereafter.

	/s/ Andrew Cronauer, Attorney-in-Fact	12/12/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.